significantly higher baseline sclerostin than women ( 39 , 40 , 41 ). We were unable to demonstrate a positive or negative effect of cosyntropin on serum sclerostin levels. It is difficult to prove a negative effect. However, power calculations using our
Search Results
Sarah Zaheer, Kayla Meyer, Rebecca Easly, Omar Bayomy, Janet Leung, Andrew W Koefoed, Mahyar Heydarpour, Roy Freeman, and Gail K Adler
Rafaella Sales de Freitas, Thiago F A França, and Sabine Pompeia
status and kisspeptin concentrations ( 1 , 7 , 9 , 15 , 18 , 19 ), we controlled for these factors. Participants’ SES was assessed based on family purchasing power, in accordance with the guidelines of the Brazilian Association of Market Research
Panisa Hantrakun, Rattanaporn Sekararithi, Thidarat Jaiwongkam, Sirinart Kumfu, Chatree Chai-adisaksopha, Nipon Chattipakorn, Theera Tongsong, and Phudit Jatavan
power of 90% at a 95% CI with the acceptable error of 0.1. This estimation is based on a study reported by Holmes et al . ( 30 ), who showed the mean P-selectin 55.4 ± 17.1 ng/mL vs 40.7 ± 16.9 ng/mL in the cases and controls. Results During
Simon Chang, Arkadiusz J Goszczak, Anne Skakkebæk, Jens Fedder, Anders Bojesen, M Vakur Bor, Moniek P M de Maat, Claus H Gravholt, and Anna-Marie B Münster
positive association between fibrin clot lysis and testosterone levels. Subgroup analysis in KS or controls alone fell short of being statistically significant, potentially due to power issues. We have previously published epidemiological data supporting
Régis Coutant, Maithé Tauber, Béatrice Demaret, Robin Henocque, Yves Brault, François Montestruc, Olivier Chassany, Michel Polak, and
ρ = 0 ( α = 0.05 two-sided) for the level of the overall life interference total score according to the GH treatment duration (analyzed as a continuous variable) had 90% power to detect a correlation coefficient ρ of at least 0.25. The
John E M Midgley, Rolf Larisch, Johannes W Dietrich, and Rudolf Hoermann
considerable inter-individual variation, these measures apparently lack statistical power in a trial setting and have not been clearly linked to prognosis. For example, even a change in thyroid function as profound as the transition from the hypothyroid to the
Nicolai Preisler, Pascal Laforêt, Karen Lindhardt Madsen, Edith Husu, Christoffer Rasmus Vissing, Gitte Hedermann, Henrik Galbo, Christopher Lindberg, and John Vissing
with an un-paired t -test). Data from a previous study were used to estimate sample size, and PS Power and Sample Size, version 3.0.0.43. was used to calculate the sample size for the primary outcomes ( 21 , 22 ). Statistical analysis was performed
Malin Nylander, Signe Frøssing, Caroline Kistorp, Jens Faber, and Sven O Skouby
at Rigshospitalet, Copenhagen, Denmark. Statistics A sample size calculation based on an estimated standard deviation of 130 units obtained from in-house data, declared 63 subjects, randomized 2:1, needed for 80% power to find a difference in
Benjamin G Challis, Andrew S Powlson, Ruth T Casey, Carla Pearson, Brian Y Lam, Marcella Ma, Deborah Pitfield, Giles S H Yeo, Edmund Godfrey, Heok K Cheow, V Krishna Chatterjee, Nicholas R Carroll, Ashley Shaw, John R Buscombe, and Helen L Simpson
powered, controlled clinical trials. Thus, reporting outcomes from patient series remains a vital conduit for disseminating evidence that additional therapies may be used safely and effectively to manage refractory hypoglycaemia in this rare and clinically
Bingbing Wang, Mayra Cruz Ithier, Nataliya Parobchak, Stacy M Yadava, Jay Schulkin, and Todd Rosen
performed using a StepOne Plus Real Time PCR System (Applied Biosystems) and power SYBR green PCR master (ThermoFisher Scientific). PCR primers (forward/reverse) included CRH, 5′-GCAGTTAGCACAGCAAGCTCAC-3′/5′-CAAATGGCATAAGAGCAGCG-3′; COX-2, 5
